A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma

Siesky, Brent; Harris, Alon; Cantor, Louis B.; Kagemann, Larry; Weitzman, Y.; McCranor, L.; Marques, Clarice; Werne, Adam; Stefánsson, Einar

doi:10.1136/bjo.2007.125187

Cited by 71 publications

(59 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Brinzolamide as well as dorzolamide have also been found to increase ONH, choroidal and retinal blood flow in patients with glaucoma and experimental animals in several studies. [63][64][65][66][67] One study indicated that treatment with dorzolamide normalizes retinal blood flow regulation in patients with glaucoma. 68 This is in agreement with data showing that a 6-month treatment with dorzolamide normalizes the ocular pressure/flow relationship.…”

Section: Topical Therapiesmentioning

confidence: 99%

Pharmacotherapy of Glaucoma

Schmidl

Schmetterer²,

Garhöfer³

et al. 2015

Journal of Ocular Pharmacology and Therapeutics

136

View full text Add to dashboard Cite

Glaucoma is a group of diseases involving the optic nerve and associated structures, which is characterized by progressive visual field loss and typical changes of the optic nerve head (ONH). The only known treatment of the disease is reduction of intraocular pressure (IOP), which has been shown to reduce glaucoma progression in a variety of large-scale clinical trials. Nowadays, a relatively wide array of topical antiglaucoma drugs is available, including prostaglandin analogues, carbonic anhydrase inhibitors, beta-receptor antagonists, adrenergic agonists, and parasympathomimetics. In clinical routine, this allows for individualized treatment taking risk factors, efficacy, and safety into account. A major challenge is related to adherence to therapy. Sustained release devices may help minimize this problem but are not yet available for clinical routine use. Another hope arises from non-IOP-related treatment concepts. In recent years, much knowledge has been gained regarding the molecular mechanisms that underlie the disease process in glaucoma. This also strengthens the hope that glaucoma therapy beyond IOP lowering will become available. Implementing this concept with clinical trials remains, however, a challenge.

show abstract

Section: Topical Therapiesmentioning

confidence: 99%

Pharmacotherapy of Glaucoma

Schmidl

Schmetterer²,

Garhöfer³

et al. 2015

Journal of Ocular Pharmacology and Therapeutics

136

View full text Add to dashboard Cite

show abstract

“…Brinzolamide (Brz), one of the carbonic anhydrase inhibitors, is effective in reducing IOP for glaucoma therapy mainly through decreasing the production of the aqueous humor (4). Its aqueous solubility is very low at pH 7.4 (25°C) probably due to its high lipophilicity.…”

Section: Introductionmentioning

confidence: 99%

Liposomes as a Novel Ocular Delivery System for Brinzolamide: In Vitro and In Vivo Studies

Liu

Zhang

et al. 2015

AAPS PharmSciTech

View full text Add to dashboard Cite

ABSTRACT. The objective of this study was to investigate the potential of liposomes as an ophthalmic delivery system for brinzolamide (Brz) to enhance the local glaucomatous therapeutic effect. The liposomes of Brz (Brz-LPs) were produced by the thin-film dispersion method with a particle size of 84.33± 2.02 nm and an entrapment efficiency of 98.32±1.61%. Differential scanning calorimetry (DSC) and X-ray powder diffraction (XRD) analysis proved that Brz was successfully entrapped into Brz-LPs. Brz-LPs displayed a biphasic release pattern in vitro with burst release initially and sustained release afterwards. The corneal permeability was measured using modified Franz-type diffusion cells, and Brz-LPs showed 6.2-fold increase in the apparent permeability coefficient when compared with the commercial available formulation (Brz-Sus). Moreover, Brz-LPs (1 mg/mL Brz) showed a more sustained and effective intraocular pressure reduction (5-10 mmHg) than Brz-Sus (10 mg/mL Brz) in white New Zealand rabbits. Therefore, Brz-LPs were a hopeful formulation of Brz for glaucoma treatment and worthy of further investigation.

show abstract

“…Studies using various retinal oximetry devices to measure the oxygen saturation of the retinal vasculature in glaucoma have been reported. [12][13][14][15][16][17][18][19][20] Hyperspectral imaging combines spectroscopy with digital imaging whereby spectral data (using numerous contiguous wavelengths of light) are obtained in every pixel of an image plane. An oximetry study of the retinal vascular network using a hyperspectral imaging system (images acquired using more than three contiguous wavelengths) in glaucoma has not yet been reported.…”

Section: Introductionmentioning

confidence: 99%

Oxygen saturation measurements of the retinal vasculature in treated asymmetrical primary open-angle glaucoma using hyperspectral imaging

Mordant

Alabboud

Muyo

et al. 2014

Eye

View full text Add to dashboard Cite

Purpose To determine whether there are differences in retinal vascular oxygen saturation measurements, estimated using a hyperspectral fundus camera, between normal eyes and treated eyes of subjects with asymmetrical primary open-angle glaucoma (POAG). Methods A noninvasive hyperspectral fundus camera was used to acquire spectral images of the retina at wavelengths between 556 and 650 nm in 2-nm increments. In total, 14 normal eyes and both eyes of 11 treated POAG subjects were imaged and analyzed using algorithms that use the spectral variation of the optical densities of blood vessels to estimate the oxygen saturation of blood within the retinal vasculature. In the treated POAG group, each of the eyes were categorized, based on the mean deviation of the Humphrey visual-field analyzer result, as either more-advanced or less-advanced, glaucomatous eyes. Unpaired t-tests (twotailed) with Welch's correction were used to compare the mean oxygen saturation between the normal subjects and the treated POAG subgroups. Results In less-advanced and moreadvanced-treated POAG eyes, mean retinal venular oxygen saturations (48.2 ± 21.6% and 42.6 ± 18.8%, respectively) were significantly higher than in normal eyes (27.9 ± 9.9%; P ¼ 0.03 and 0.01, respectively). Arteriolar oxygen saturation was not significantly different between normal eyes and treated POAG eyes. ConclusionsThe increased oxygen saturation of the retinal venules in advancedtreated POAG eyes may indicate reduced metabolic consumption of oxygen in the inner retinal tissues.

show abstract

A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma

Abstract: This pilot study suggests that brinzolamide and dorzolamide may increase retinal oxygen saturation in patients with OAG.

Cited by 71 publications

References 47 publications

Pharmacotherapy of Glaucoma

Pharmacotherapy of Glaucoma

Liposomes as a Novel Ocular Delivery System for Brinzolamide: In Vitro and In Vivo Studies

Oxygen saturation measurements of the retinal vasculature in treated asymmetrical primary open-angle glaucoma using hyperspectral imaging

Contact Info

Product

Resources

About